Taking Mounjaro with kidney stones: what the evidence actually says

The myth worth correcting first: that a stones history rules you out

A common assumption is that any kidney condition makes GLP-1 medicines off-limits. That is not what the clinical guidance says. The NHS tirzepatide page lists the precautions and contraindications for Mounjaro; kidney stones do not feature as a contraindication, and having had a stone in the past does not automatically disqualify you. What matters more is the cause of those stones, the current state of your kidney function, and whether you have any conditions (such as primary hyperoxaluria or hypercalciuria) that put you in a persistently high-risk group.

That said, this is not a reason to dismiss the question. Tirzepatide's commonest side effects are gastrointestinal: nausea, vomiting, and diarrhoea appear most often in the first few weeks after starting or after a dose increase. Each of those reduces your fluid intake and, in some cases, increases the concentration of stone-forming minerals in urine. For someone whose stones formed partly because they were chronically under-hydrated, that early GI phase is a period of real, practical risk. It is not a theoretical concern.

The fix is not to avoid the medicine; it is to go in informed, with a prescriber who knows your history. If you want more detail on the specific kidney-related questions around tirzepatide, our overview of tirzepatide and kidney stones covers the mechanism and evidence in full.

Where dehydration and stone risk intersect during treatment

Kidney stones form when minerals crystallise in concentrated urine. The single most modifiable risk factor for most stone types is inadequate fluid intake. Tirzepatide does not cause kidney stones directly, but the GI side effects that accompany the early weeks of treatment can indirectly push in that direction, particularly for people who already form stones easily.

Vomiting reduces the fluid you retain. Nausea suppresses the urge to drink. Diarrhoea accelerates fluid loss. Taken together during the 2.5mg and 5mg starting phases, these effects can meaningfully reduce urine volume if someone is not deliberately compensating. Prescribers often advise aiming for pale, straw-coloured urine as a practical daily check, and increasing fluid intake above a person's usual baseline during the weeks when GI symptoms are most active.

It is also worth noting that tirzepatide can cause a reduction in blood pressure and some change in creatinine levels in certain patients, which is one reason kidney function monitoring is relevant for people with pre-existing kidney disease. If you are specifically asking about using Mounjaro alongside kidney disease, that question deserves its own careful answer.

Our clinical team reviews each consultation individually, with full sight of a patient's medical history, before any prescription is issued.

What a prescriber needs to know, and what remains genuinely uncertain

Before starting tirzepatide, tell your prescriber specifically: that you have had kidney stones, how recently, what type if you know it, whether you have had more than one episode, and whether you have ever been investigated for an underlying metabolic cause. If you are already under a nephrologist or urologist, flag that too. None of this will necessarily prevent approval, but it shapes the conversation around monitoring and hydration targets.

What remains less settled in the published literature is whether tirzepatide has any direct effect on stone-forming pathways. The medicine influences uric acid levels in some patients (and uric acid stones are one stone type) but the clinical significance of this for people without gout or hyperuricaemia is not clearly established. The SURMOUNT trial programme, involving thousands of adults, did not identify kidney stones as a significant adverse signal, though trial populations are not the same as real-world stone-formers who are specifically at risk. The honest answer is that large, long-term data in this sub-group do not yet exist.

For questions about whether tirzepatide might itself contribute to new stone formation, this page looks at that specific concern in more detail. Anyone who wants a broader look at the relationship between this medicine and stone risk will find that our page covering Mounjaro and kidney stones brings together the key evidence and practical considerations. The MHRA runs a Yellow Card scheme for suspected side effects; anyone experiencing new or worsening urinary symptoms while on tirzepatide can report them at yellowcard.mhra.gov.uk.

How to start the conversation, and what comes next

If you are considering tirzepatide and have a kidney stone history, the right move is a clinical consultation, not a search through forums. A prescriber can ask the questions that actually matter: your stone type, your hydration patterns, whether your kidney function has been tested recently, and whether you take any medicines that affect urine chemistry.

At nume, a GPhC-registered Independent Prescriber reads your consultation the same day, a real clinician, not automated triage. If approved, your medication is dispatched the same day (for orders placed before 12pm, Monday to Friday), arriving via DPD in plain, unbranded packaging with no indication of the contents. The pen itself is a pre-filled KwikPen; instructions and full safety information come with it, including the Patient Information Leaflet which covers storage and what to do if GI symptoms are severe.

You can read about the weight-loss treatments we prescribe or look at Mounjaro pricing context before you start. When you are ready, speak to our prescribers, it is a free consultation, and kidney stones are exactly the kind of detail worth raising from the outset.